Desflurane-Induced Delayed Onset of Malignant Hyperthermia: A Case Report.

Hideaki Seki, Niki Takei, Mie Kajiwara, Madoka Tsumura, Nozomi Naito, Miho Tsujiuchi, Mami Higa, Yuko Koyanagi, Shunichi Oka, Keisuke Kaneko
{"title":"Desflurane-Induced Delayed Onset of Malignant Hyperthermia: A Case Report.","authors":"Hideaki Seki, Niki Takei, Mie Kajiwara, Madoka Tsumura, Nozomi Naito, Miho Tsujiuchi, Mami Higa, Yuko Koyanagi, Shunichi Oka, Keisuke Kaneko","doi":"10.2344/25-0006","DOIUrl":null,"url":null,"abstract":"<p><p>Malignant hyperthermia (MH) is a rare but life-threatening pharmacogenetic disorder triggered by volatile anesthetics and/or depolarizing muscle relaxants, resulting in a hypermetabolic crisis. We report a case of postoperative fulminant MH in a 26-year-old man who underwent general anesthesia with desflurane and rocuronium for mandibular fracture repair. Despite a history of multiple uneventful anesthetics, the patient developed acute hypercapnia, tachycardia, muscle rigidity, and rapid hyperthermia during emergence, following sugammadex administration. Initial treatment for presumed bronchospasm and postoperative shivering-including sevoflurane sedation, hyperventilation, and inhaled bronchodilators-proved ineffective. A clinical diagnosis of MH was made based on the progression of clinical findings, and treatment with intravenous dantrolene 100 mg, active cooling, and antipyretics was initiated. The patient responded well to intervention and recovered without sequelae. This case highlights the importance of considering MH even in the postoperative phase, particularly with the use of desflurane and potentially contributory agents such as sugammadex and ondansetron. Early clinical suspicion, rapid administration of dantrolene, and supportive measures are critical for favorable outcomes. Anesthesia providers must remain vigilant for MH at all perioperative stages and ensure that emergency protocols, appropriate drug stock, and staff readiness are in place.</p>","PeriodicalId":94296,"journal":{"name":"Anesthesia progress","volume":"73 2","pages":"97-105"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266616/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesia progress","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2344/25-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Malignant hyperthermia (MH) is a rare but life-threatening pharmacogenetic disorder triggered by volatile anesthetics and/or depolarizing muscle relaxants, resulting in a hypermetabolic crisis. We report a case of postoperative fulminant MH in a 26-year-old man who underwent general anesthesia with desflurane and rocuronium for mandibular fracture repair. Despite a history of multiple uneventful anesthetics, the patient developed acute hypercapnia, tachycardia, muscle rigidity, and rapid hyperthermia during emergence, following sugammadex administration. Initial treatment for presumed bronchospasm and postoperative shivering-including sevoflurane sedation, hyperventilation, and inhaled bronchodilators-proved ineffective. A clinical diagnosis of MH was made based on the progression of clinical findings, and treatment with intravenous dantrolene 100 mg, active cooling, and antipyretics was initiated. The patient responded well to intervention and recovered without sequelae. This case highlights the importance of considering MH even in the postoperative phase, particularly with the use of desflurane and potentially contributory agents such as sugammadex and ondansetron. Early clinical suspicion, rapid administration of dantrolene, and supportive measures are critical for favorable outcomes. Anesthesia providers must remain vigilant for MH at all perioperative stages and ensure that emergency protocols, appropriate drug stock, and staff readiness are in place.

地氟醚致迟发性恶性高热1例报告。
恶性热疗(MH)是一种罕见但危及生命的药物遗传疾病,由挥发性麻醉剂和/或去极化肌肉松弛剂引发,导致高代谢危机。我们报告一例术后暴发性MH在一个26岁的男子谁接受全身麻醉地氟醚和罗库溴铵下颌骨骨折修复。尽管有多种麻醉史,但患者在给药后出现急性高碳酸血症、心动过速、肌肉僵硬和急诊时快速高热。初步治疗支气管痉挛和术后寒颤,包括七氟醚镇静、过度通气和吸入支气管扩张剂,均无效。根据临床表现的进展作出MH的临床诊断,并开始静脉注射丹曲林100mg,主动降温和退烧药治疗。患者对干预反应良好,康复无后遗症。该病例强调了即使在术后阶段也考虑MH的重要性,特别是在使用地氟醚和潜在的促成剂(如sugammadex和ondansetron)的情况下。早期临床怀疑、快速给药和支持性措施是获得良好结果的关键。麻醉提供者必须在围手术期对MH保持警惕,并确保应急方案、适当的药物储备和工作人员准备就绪。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书